156 related articles for article (PubMed ID: 26379080)
1. Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma.
Rossi L; Laas E; Mallon P; Vincent-Salomon A; Guinebretiere JM; Lerebours F; Rouzier R; Pierga JY; Reyal F
Br J Cancer; 2015 Sep; 113(7):996-1002. PubMed ID: 26379080
[TBL] [Abstract][Full Text] [Related]
2. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the Ki67 scoring categories in breast cancer subgroups.
Niikura N; Masuda S; Kumaki N; Xiaoyan T; Terada M; Terao M; Iwamoto T; Oshitanai R; Morioka T; Tuda B; Okamura T; Saito Y; Suzuki Y; Tokuda Y
Clin Breast Cancer; 2014 Oct; 14(5):323-329.e3. PubMed ID: 24492237
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
7. The Value of Ki67 in Very Young Women with Hormone Receptor-Positive Breast Cancer: Retrospective Analysis of 9,321 Korean Women.
Kim J; Han W; Jung SY; Park YH; Moon HG; Ahn SK; Lee JW; Kim MK; Kim JJ; Lee ES; You TK; Kang HS; Lee ES; Ro J; Lee JE; Nam SJ; Yim YH; Park IA; Noh DY
Ann Surg Oncol; 2015 Oct; 22(11):3481-8. PubMed ID: 25652052
[TBL] [Abstract][Full Text] [Related]
8. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
9. The potential utility of geminin as a predictive biomarker in breast cancer.
Sundara Rajan S; Hanby AM; Horgan K; Thygesen HH; Speirs V
Breast Cancer Res Treat; 2014 Jan; 143(1):91-8. PubMed ID: 24292956
[TBL] [Abstract][Full Text] [Related]
10. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
[TBL] [Abstract][Full Text] [Related]
11. Quantum dot-based multispectral fluorescent imaging to quantitatively study co-expressions of Ki67 and HER2 in breast cancer.
Xiang QM; Wang LW; Yuan JP; Chen JM; Yang F; Li Y
Exp Mol Pathol; 2015 Aug; 99(1):133-8. PubMed ID: 26102249
[TBL] [Abstract][Full Text] [Related]
12. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
13. Combined analysis of vascular invasion, grade, HER2 and Ki67 expression identifies early breast cancer patients with questionable benefit of systemic adjuvant therapy.
Synnestvedt M; Borgen E; Russnes HG; Kumar NT; Schlichting E; Giercksky KE; Kåresen R; Nesland JM; Naume B
Acta Oncol; 2013 Jan; 52(1):91-101. PubMed ID: 22934555
[TBL] [Abstract][Full Text] [Related]
14. Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index.
Jalava P; Kuopio T; Juntti-Patinen L; Kotkansalo T; Kronqvist P; Collan Y
Histopathology; 2006 May; 48(6):674-82. PubMed ID: 16681683
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer.
Jerjees DA; Alabdullah M; Green AR; Alshareeda A; Macmillan RD; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2014 Jun; 145(2):317-30. PubMed ID: 24744091
[TBL] [Abstract][Full Text] [Related]
16. Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer.
Eggemann H; Ignatov T; Burger E; Kantelhardt EJ; Fettke F; Thomssen C; Costa SD; Ignatov A
Endocr Relat Cancer; 2015 Oct; 22(5):725-33. PubMed ID: 26187126
[TBL] [Abstract][Full Text] [Related]
17. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
[TBL] [Abstract][Full Text] [Related]
18. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer.
Criscitiello C; Disalvatore D; De Laurentiis M; Gelao L; Fumagalli L; Locatelli M; Bagnardi V; Rotmensz N; Esposito A; Minchella I; De Placido S; Santangelo M; Viale G; Goldhirsch A; Curigliano G
Breast; 2014 Feb; 23(1):69-75. PubMed ID: 24314620
[TBL] [Abstract][Full Text] [Related]
19. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
[TBL] [Abstract][Full Text] [Related]
20. Prognostic comparison of the proliferation markers (mitotic activity index, phosphohistone H3, Ki67), steroid receptors, HER2, high molecular weight cytokeratins and classical prognostic factors in T₁₋₂N₀M₀ breast cancer.
Gudlaugsson E; Klos J; Skaland I; Janssen EA; Smaaland R; Feng W; Shao Z; Malpica A; Baak JP
Pol J Pathol; 2013 Apr; 64(1):1-8. PubMed ID: 23625593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
